Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (161-170 of 334) with videos related to

Pageof 34
Sort By:
Urologia Internationalis|January 5, 2017
Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate CancerFilip Poelaert, Candy Kumps, Nicolaas Lumen, et al.
World Journal of Urology|September 19, 2023
Stereotactic body radiation therapy after radical prostatectomy: current status and future directionsJennifer Le Guevelou, Nicolas Magne, Felipe Counago, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2025
Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical TrialCarole Mercier, Charlotte Billiet, Piet Ost, et al.
Urologic Oncology|October 1, 2018
Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary updateIgor Tsaur, Isabel Heidegger, Alexander Kretschmer, et al.
BJU International|September 20, 2025
Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancerLies Van den Eynde, Piet Ost, Wesley Verla, et al.
Radiation Oncology (London, England)|July 31, 2014
Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trialAnnemieke De Puysseleyr, Joris Van De Velde, Bruno Speleers, et al.
Nature Reviews. Urology|December 6, 2022
Using PSMA imaging for prognostication in localized and advanced prostate cancerMatthew J Roberts, Tobias Maurer, Marlon Perera, et al.
Oncotarget|June 5, 2018
Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profileAnnabel Meireson, Inès Chevolet, Eva Hulstaert, et al.
European Journal of Cancer Care|May 23, 2019
Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CTAlfonso Gomez-Iturriaga, Francisco Casquero Ocio, Piet Ost, et al.
BMC Cancer|September 17, 2014
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialKarel Decaestecker, Gert De Meerleer, Filip Ameye, et al.
Pageof 34

Showing results (161-170 of 334) with videos related to

Sort By:
Pageof 34
Urologia Internationalis|January 5, 2017
Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate CancerFilip Poelaert, Candy Kumps, Nicolaas Lumen, et al.
World Journal of Urology|September 19, 2023
Stereotactic body radiation therapy after radical prostatectomy: current status and future directionsJennifer Le Guevelou, Nicolas Magne, Felipe Counago, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2025
Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical TrialCarole Mercier, Charlotte Billiet, Piet Ost, et al.
Urologic Oncology|October 1, 2018
Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary updateIgor Tsaur, Isabel Heidegger, Alexander Kretschmer, et al.
BJU International|September 20, 2025
Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancerLies Van den Eynde, Piet Ost, Wesley Verla, et al.
Radiation Oncology (London, England)|July 31, 2014
Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trialAnnemieke De Puysseleyr, Joris Van De Velde, Bruno Speleers, et al.
Nature Reviews. Urology|December 6, 2022
Using PSMA imaging for prognostication in localized and advanced prostate cancerMatthew J Roberts, Tobias Maurer, Marlon Perera, et al.
Oncotarget|June 5, 2018
Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profileAnnabel Meireson, Inès Chevolet, Eva Hulstaert, et al.
European Journal of Cancer Care|May 23, 2019
Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CTAlfonso Gomez-Iturriaga, Francisco Casquero Ocio, Piet Ost, et al.
BMC Cancer|September 17, 2014
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialKarel Decaestecker, Gert De Meerleer, Filip Ameye, et al.
Pageof 34